Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

The usual first treatment for Pneumocystis jirovecii pneumonia (PCP) is an antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX). However, some patients cannot take this medication because of allergies, side effects, or lack of response. This study asks the question: When TMP-SMX cannot be used, which alternative treatment for PCP provides the best balance of effectiveness and safety?

NCT Number	NCT07357103
Lead Sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions	Pneumocystis, Pneumocystis Infection, Pneumocystis Carinii Infection, Pneumocystis Carinii; Infection, Resulting From HIV Disease, Pneumocystis Jirovecii Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystosis Associated With AIDS, Pneumocystosis; Pneumonia (Etiology)
Enrollment	416 participants
Start Date	2026-03
Primary Completion	2029-03 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2026-01-21